NSE - Delayed Quote INR

Gland Pharma Limited (GLAND.NS)

1,426.00
+10.40
+(0.73%)
At close: 3:29:52 PM GMT+5:30
Loading Chart for GLAND.NS
  • Previous Close 1,415.60
  • Open 1,400.00
  • Bid --
  • Ask --
  • Day's Range 1,384.40 - 1,428.50
  • 52 Week Range 1,277.80 - 2,220.95
  • Volume 91,064
  • Avg. Volume 325,163
  • Market Cap (intraday) 234.942B
  • Beta (5Y Monthly) 0.27
  • PE Ratio (TTM) 33.36
  • EPS (TTM) 42.75
  • Earnings Date May 20, 2025
  • Forward Dividend & Yield 20.00 (1.41%)
  • Ex-Dividend Date Aug 16, 2024
  • 1y Target Est 1,712.91

Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. The company engages in research and development of pharmaceutical active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The company offers its products for various therapeutic categories, such as anti-malarial, anti-infectives, anti-neoplastic, blood related, cardiac, gastrointestinal, gynaecological, hormones, neuro/Cns, ophthal/otological, and other areas, as well as pain and analgesics, respiratory, and vitamins, minerals, and nutrients; and contract development services. The company was incorporated in 1978 and is headquartered in Hyderabad, India. Gland Pharma Limited operates as a subsidiary of Fosun Pharma Industrial Pte. Ltd.

www.glandpharma.com

4,217

Full Time Employees

March 31

Fiscal Year Ends

Recent News: GLAND.NS

View More

Performance Overview: GLAND.NS

Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .

YTD Return

GLAND.NS
19.86%
S&P BSE SENSEX (^BSESN)
1.68%

1-Year Return

GLAND.NS
14.90%
S&P BSE SENSEX (^BSESN)
9.74%

3-Year Return

GLAND.NS
52.47%
S&P BSE SENSEX (^BSESN)
45.87%

5-Year Return

GLAND.NS
16.61%
S&P BSE SENSEX (^BSESN)
151.10%

Compare To: GLAND.NS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: GLAND.NS

View More

Valuation Measures

Annual
As of 5/8/2025
  • Market Cap

    233.23B

  • Enterprise Value

    207.19B

  • Trailing P/E

    33.11

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    4.09

  • Price/Book (mrq)

    2.65

  • Enterprise Value/Revenue

    3.63

  • Enterprise Value/EBITDA

    13.93

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    12.30%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    57.29B

  • Net Income Avi to Common (ttm)

    7.04B

  • Diluted EPS (ttm)

    42.75

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    28.2B

  • Total Debt/Equity (mrq)

    3.72%

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: GLAND.NS

View More

Company Insights: GLAND.NS

Research Reports: GLAND.NS

View More

People Also Watch